KWA
STLN

Kingswood Wealth Advisors’s Starling Oncology STLN Stock Holding History

Kingswood Wealth Advisors’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$662K Buy
121,900
+18,700
+18% +$78.5K 0.03% 528
2026
Q1 		$317K Buy
103,200
+4,500
+5% +$13.8K 0.02% 691
2025
Q4 		$351K Buy
98,700
+21,100
+27% +$78.3K 0.02% 628
2025
Q3 		$271K Buy
77,600
+13,200
+20% +$45.2K 0.02% 662
2025
Q2 		$132K Buy
+64,400
New +$161K 0.01% 725

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Kingswood Wealth Advisors's STLN Position: Q2 2026 in Review

Kingswood Wealth Advisors increased its Starling Oncology (STLN) stake by 18% in Q2 2026, buying an estimated $78.5K and bringing the position to 121,900 shares worth $662K. The position accounts for 0.03% of the portfolio, ranked #528.

Kingswood Wealth Advisors first reported a position in STLN in Q2 2025 and has held it in 5 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Kingswood Wealth Advisors held 121,900 shares of Starling Oncology worth $662K as of Q2 2026.
  • Kingswood Wealth Advisors bought 18,700 Starling Oncology shares in Q2 2026, an estimated $78.5K.
  • Starling Oncology made up 0.03% of Kingswood Wealth Advisors's portfolio in Q2 2026, its #528 holding.
  • Kingswood Wealth Advisors first reported a position in Starling Oncology in Q2 2025 and has held it in 5 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Kingswood Wealth Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.